Dr. Robert Stowe

Dr. Robert (Bob) Stowe is a behavioral neurologist based in the UBC Neuropsychiatry Program, where his clinical and research efforts focus on neuropsychiatric genetics. He also consults to the tertiary BC Psychosis Unit located at UBC Hospital, and the PHSA-run inpatient Provincial Assessment Centre for individuals with autism and/or intellectual disability complicated by major psychiatric disorders; and runs the Delta Hospital Neuropsychiatry Outpost for Fraser Health. He co-directs the MAGERS (Metabolic and Genetic Explorations in Refractory Schizophrenia) research project with Prescilla Carrion, a psychiatric genetic counselor.

Bob completed his MD at Queen’s University, internships and neurology residency at the University of Toronto (where he also pursued graduate studies in philosophy of mind), and a behavioral neurology fellowship at Harvard Medical School. Aften ten years at the University of Pittsburgh,  where he was a founding member of the joint Pitt-Carnegie Mellon Center for the Neural Basis of Cognition, he moved to UBC in 1998, and directed Riverview Hospital’s Acute Neuropsychiatric Assessment and Rehabilitation Unit from 1999 to 2007.

Bob served on the Genetic Testing Task Force of the International Society for Psychiatric Genetics, has been a member of the UBC Clinical Research Ethics Board since 2007, and currently co-chairs the American Neuropsychiatric Association’s Neuropsychiatric Genetics Special Interest Group. He also volunteers with a number of climate justice organizations, including Doctors for Planetary Health – West Coast and Canadian Association of Physicians for the Environment, and sits on the board of Be The Change Earth Alliance.

View an extended list of peer-reviewed publications on ORCID

• T74. HIGH YIELD OF DEEP PHENOTYPING AND LONG READ WHOLE GENOME SEQUENCING IN TREATMENT-RESISTANT PSYCHOSIS European Neuropsychopharmacology2024-10 | journal-article
  • DOI: 10.1016/j.euroneuro.2024.08.384
  • Part of ISSN: 0924-977X
  • Source:Robert Stowe
• SETD1A variant-associated psychosis: A systematic review of the clinical literature and description of two new cases Progress in Neuro-Psychopharmacology and Biological Psychiatry2024 | journal-article
  • DOI: 10.1016/j.pnpbp.2023.110888
  • EID: 2-s2.0-85175449821
  • Part of ISSN: 18784216 02785846
  • Source:Robert StoweviaScopus – Elsevier
• The curious absence of psychosis in GRIN1-related neurodevelopmental disorder European Archives of Psychiatry and Clinical Neuroscience2024 | journal-article
  • DOI: 10.1007/s00406-024-01796-x
  • EID: 2-s2.0-85187875745
  • Part of ISSN: 14338491 09401334
  • Source:Robert StoweviaScopus – Elsevier
• Virtual twins for model-informed precision dosing of clozapine in patients with treatment-resistant schizophrenia CPT: Pharmacometrics and Systems Pharmacology2024 | journal-article
  • DOI: 10.1002/psp4.13093
  • EID: 2-s2.0-85182868341
  • Part of ISSN: 21638306
  • Source:Robert StoweviaScopus – Elsevier
• A 1p31.3 deletion encompassing the nuclear factor 1A gene presenting as possible temporal lobe epilepsy in association with schizoaffective disorder Neurocase2022-10-09 | journal-article
  • DOI: 10.1080/13554794.2022.2132869Part of ISSN: 1355-4794Source:Robert StoweviaCrossref Metadata Search
• ASSESSING THE UTILITY OF PHARMACOGENETIC TESTING IN A COHORT WITH TREATMENT-RESISTANT SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER European Neuropsychopharmacology2022-10 | journal-article
  • DOI: 10.1016/j.euroneuro.2022.07.282
  • Part of ISSN: 0924-977X
  • Source:Robert StoweviaCrossref Metadata Search
• Subjective cognitive functioning, depressive symptoms, and objective cognitive functioning in people with treatment-resistant psychosis Cognitive Neuropsychiatry2022-08-05 | journal-article
  • DOI: 10.1080/13546805.2022.2108389
  • Part of ISSN: 1354-6805
  • Source:Robert StoweviaCrossref Metadata Search
• Progressive neurocognitive decline in schizophrenia: A diagnostic dilemma for clinicians Schizophrenia Research2022-03 | journal-article
  • DOI: 10.1016/j.schres.2022.01.027.Part of ISSN: 0920-9964Source:Robert Stowe
• Whole-genome sequencing analysis of clozapine-induced myocarditis Pharmacogenomics Journal2022 | journal-article
  • DOI: 10.1038/s41397-022-00271-x
  • EID: 2-s2.0-85128780594
  • Part of ISSN: 14731150 1470269X
  • Source:Robert StoweviaScopus – Elsevier
• TU71. SIGNIFICANT INCIDENCE OF RARE CHROMOSOMAL AND GENOMIC SEQUENCE VARIANTS IN HIGHLY TREATMENT-RESISTANT SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER European Neuropsychopharmacology2021-10 | journal-article
  • DOI: 10.1016/j.euroneuro.2021.08.073Part of ISSN: 0924-977XSource:Robert Stowe
• Review and Consensus on Pharmacogenomic Testing in Psychiatry Pharmacopsychiatry2021 | journal-article
  • DOI: 10.1055/a-1288-1061EID: 2-s2.0-85096126177Part of ISSN: 14390795 01763679Source:Robert StoweviaScopus – Elsevier
• First Whole Transcriptome RNAseq on CHD8 Haploinsufficient Patient and Meta-Analyses Across Cellular Models Uncovers Likely Key Pathophysiological Target Genes Cureus2020-11-19 | journal-article
  • DOI: 10.7759/cureus.11571
  • Part of ISSN: 2168-8184
  • Source:Robert Stowe
• Treatment-resistant psychotic symptoms and early-onset dementia: A case report of the 3q29 deletion syndrome Schizophrenia Research2020-09 | journal-article
  • DOI: 10.1016/j.schres.2020.08.012
  • Part of ISSN: 0920-9964
  • Source:Robert Stowe
• Clinical and biochemical footprints of inherited metabolic diseases. III. Psychiatric presentations. Molecular genetics and metabolism2020-02 | journal-article
  • PMID: 32122747
  • DOI: 10.1016/j.ymgme.2020.02.007
  • Source:Robert StoweviaEurope PubMed Central